JPH09505725A - セマホリン遺伝子群 - Google Patents
セマホリン遺伝子群Info
- Publication number
- JPH09505725A JPH09505725A JP7509261A JP50926195A JPH09505725A JP H09505725 A JPH09505725 A JP H09505725A JP 7509261 A JP7509261 A JP 7509261A JP 50926195 A JP50926195 A JP 50926195A JP H09505725 A JPH09505725 A JP H09505725A
- Authority
- JP
- Japan
- Prior art keywords
- semaphorin
- peptide
- sequence
- receptor
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108050003978 Semaphorin Proteins 0.000 title claims abstract description 154
- 102000014105 Semaphorin Human genes 0.000 claims abstract description 138
- 238000000034 method Methods 0.000 claims abstract description 65
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 30
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 24
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 24
- 239000000523 sample Substances 0.000 claims abstract description 14
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 5
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 122
- 210000004027 cell Anatomy 0.000 claims description 89
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 69
- 102000005962 receptors Human genes 0.000 claims description 69
- 108020003175 receptors Proteins 0.000 claims description 69
- 230000027455 binding Effects 0.000 claims description 38
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 210000000020 growth cone Anatomy 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 23
- 210000002569 neuron Anatomy 0.000 claims description 22
- 229940079593 drug Drugs 0.000 claims description 21
- 230000006870 function Effects 0.000 claims description 21
- 108020004414 DNA Proteins 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 238000002955 isolation Methods 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 241000700605 Viruses Species 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 101700012268 Holin Proteins 0.000 claims description 5
- 241000700618 Vaccinia virus Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000009261 transgenic effect Effects 0.000 claims description 5
- 241000283984 Rodentia Species 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 210000001082 somatic cell Anatomy 0.000 claims 4
- 102000027411 intracellular receptors Human genes 0.000 claims 3
- 108091008582 intracellular receptors Proteins 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 230000003955 neuronal function Effects 0.000 claims 2
- 230000007918 pathogenicity Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 108010091748 peptide A Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 69
- 102000004169 proteins and genes Human genes 0.000 abstract description 54
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 23
- 238000011161 development Methods 0.000 abstract description 15
- 230000018109 developmental process Effects 0.000 abstract description 15
- 238000012216 screening Methods 0.000 abstract description 11
- 241001465754 Metazoa Species 0.000 abstract description 6
- 239000000126 substance Substances 0.000 abstract description 6
- 230000002068 genetic effect Effects 0.000 abstract description 4
- 230000005709 nerve cell growth Effects 0.000 abstract description 4
- 239000002464 receptor antagonist Substances 0.000 abstract description 3
- 229940044551 receptor antagonist Drugs 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000001413 cellular effect Effects 0.000 abstract description 2
- 238000013507 mapping Methods 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 53
- 210000003050 axon Anatomy 0.000 description 50
- 230000037361 pathway Effects 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 27
- 239000002299 complementary DNA Substances 0.000 description 27
- 101000684301 Schistocerca americana Semaphorin-1A Proteins 0.000 description 26
- 241000254032 Acrididae Species 0.000 description 22
- 230000015572 biosynthetic process Effects 0.000 description 16
- 210000002257 embryonic structure Anatomy 0.000 description 16
- 210000003414 extremity Anatomy 0.000 description 15
- 239000003446 ligand Substances 0.000 description 15
- 210000003169 central nervous system Anatomy 0.000 description 14
- 210000001161 mammalian embryo Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 108700026244 Open Reading Frames Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- 210000004394 hip joint Anatomy 0.000 description 12
- 101000650815 Mus musculus Semaphorin-4C Proteins 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 230000006698 induction Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 101000802896 Dendroaspis angusticeps Dendrotoxin A Proteins 0.000 description 10
- 101000802897 Dendroaspis polylepis polylepis Acetylcholinesterase toxin C Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 239000011574 phosphorus Substances 0.000 description 8
- 230000009870 specific binding Effects 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 101000632261 Homo sapiens Semaphorin-3A Proteins 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 7
- 230000002159 abnormal effect Effects 0.000 description 7
- 102000057183 human SEMA3A Human genes 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 210000000982 limb bud Anatomy 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 101100042271 Mus musculus Sema3b gene Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000001624 hip Anatomy 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 5
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003376 axonal effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000254086 Tribolium <beetle> Species 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 241000700647 Variola virus Species 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 210000000689 upper leg Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 108091036078 conserved sequence Proteins 0.000 description 3
- -1 cyclohexyl alanine Chemical compound 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000013601 eggs Nutrition 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000003365 immunocytochemistry Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000003757 neuroblast Anatomy 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 101000632255 Drosophila melanogaster Semaphorin-2A Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Chemical group 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 108010090319 Semaphorin-3A Proteins 0.000 description 2
- 102000013008 Semaphorin-3A Human genes 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000028600 axonogenesis Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001705 ectoderm cell Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 238000001400 expression cloning Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 108010037639 fasciclin I Proteins 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000002161 motor neuron Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 229910052718 tin Inorganic materials 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000238818 Acheta domesticus Species 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000534431 Hygrocybe pratensis Species 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- 101150062179 II gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 241000254022 Locusta migratoria Species 0.000 description 1
- 241000256010 Manduca Species 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000004207 Neuropilin-1 Human genes 0.000 description 1
- 108090000772 Neuropilin-1 Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000238814 Orthoptera Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101800002502 P-factor Proteins 0.000 description 1
- LUNBMBVWKORSGN-TYEKWLQESA-N P-factor Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(C(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)[C@@H](C)O)[C@@H](C)O)C(C)C)CCC1 LUNBMBVWKORSGN-TYEKWLQESA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 108010073443 Ribi adjuvant Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Chemical group OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000021617 central nervous system development Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000012973 diazabicyclooctane Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000005562 fading Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- YFHXZQPUBCBNIP-UHFFFAOYSA-N fura-2 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=3OC(=CC=3C=2)C=2OC(=CN=2)C(O)=O)N(CC(O)=O)CC(O)=O)=C1 YFHXZQPUBCBNIP-UHFFFAOYSA-N 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 102000047882 human INSR Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000001418 larval effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001617 median nerve Anatomy 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000009689 neuronal regeneration Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 210000003055 polytene chromosome Anatomy 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- YVSWPCCVTYEEHG-UHFFFAOYSA-N rhodamine B 5-isothiocyanate Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=C(N=C=S)C=C1C(O)=O YVSWPCCVTYEEHG-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220201851 rs143406017 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000011935 selective methylation Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000015541 sensory perception of touch Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000000457 tarsus Anatomy 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000017105 transposition Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009447 viral pathogenesis Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
- A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
- A01K67/0337—Genetically modified Arthropods
- A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.セマホリンの固有部分を含む少なくとも5個のアミノ酸を有する単離された ポリペプチドであって、かつセマホリン結合特異性を有する、単離されたペプチ ド。 2.前記セマホリンが、ヒトのセマホリンを含む、請求の範囲第1項記載の単離 されたペプチド。 3.請求の範囲第1項記載のペプチドと特異的に結合する、単離された抗体。 4.請求の範囲第1項記載のペプチドをコードしているヌクレオチド配列を含む 、単離された核酸であって、該配列が天然には該配列と結合しないようなヌクレ オチドと結合し、かつその配列がワクシニアウイルスのA39 ORF以外である、単 離された核酸。 5.請求の範囲第3項記載の核酸を含む細胞。 6.請求の範囲第7項記載の核酸を含むトランスジェニックゲッ歯類であって、 この核酸が、該ゲッ歯類に対して異種のものである、トランスジェニックゲッ歯 類。 7.セマホリンの組換え固有部分の生成の方法であって、該ペプチドの発現に適 した条件下で、請求の範囲第4項記載の細胞を培養する工程、及び該ペプチドを 回収する工程を含む方法。 8.セマホリン受容体へのセマホリンの結合に関連した疾患の診断又は治療に有 用な医薬品を同定する方法であって、下記の工程を含む方法: 請求の範囲第1項記載のペプチドに、見込みのある薬剤のパネルを接触する 工程; 該ペプチドへの、前述の多数の見込みのある薬剤の結合を測定する工程; 該ペプチドに特異的に結合する前述の多数の医薬品を同定する工程; ここで、該医薬品が、細胞内受容体へのセマホリンの結合に関連した疾患の 診断又は治療に有用であるような方法。 9.遺伝子座に関連した神経疾患の疾病素質について患者を診断する方法であっ て、下記の工程を含む方法: 患者から体細胞を採取する工程; 該体細胞からゲノムDNAを単離する工程; 該ゲノムDNAを、請求の範囲第1項記載のペプチドをコードしているDNA配列 を含むプローブと、該プローブが相同DNAとハイブリッド形成するような条件下 で接触する工程; 前記プローブとハイブリッド形成している該ゲノムDNAの領域を同定する工 程; ここで、該領域の配列の有無が、神経疾患の疾病素質と関連している方法。 10.神経損傷又は疾患、もしくは病的ウイルス感染症を有する患者の治療法であ って、下記の工程を含む方法: 請求の範囲第1項記載のペプチド及び医薬として許容できる担体を含有する 医薬組成物を、治療に有効な量、患者に投与する工程; ここで、前記ペプチドが、該患者において、神経細胞の成長円錐機能又はウ イルス病原性を変更する方法。 11.セマホリンのアミノ酸配列と実質的に類似のアミノ酸配列を含み、かつセマ ホリンとの結合特異性を有する、単離されたポリペプチド。 12.セマホリン受容体の固有部分を含む少なくとも5個のアミノ酸を有する単離 されたペプチドであって、セマホリン受容体結合特異性を有する、単離されたポ リペプチド。 13.請求の範囲第12項記載のペプチドと、特異的に結合する、単離された抗体。 14.請求の範囲第12項記載のペプチドをコードしているヌクレオチド配列を含む 単離された核酸であって、該配列が、天然には該配列と結合しないようなヌクレ オチドと結合している、単離された核酸。 15.請求の範囲第14項記載の核酸を含む細胞。 16.請求の範囲第12項記載のセマホリン受容体ペプチドの組換え固有部分の生成 法であって、請求の範囲第14項記載の細胞を、該ペプチド発現に適した条件下で 培養する工程、及び該ペプチドを回収する工程を含む方法。 17.細胞内受容体へのセマホリンの結合に関連した疾患の診断又は治療に有用な 医薬品を同定する方法であって、下記の工程を含む方法: 請求の範囲第12項記載のペプチドに、見込みのある薬剤のパネルを接触する 工程; 該ペプチドへの、前述の多数の見込みのある薬剤の結合を測定する工程; 該ペプチドに特異的に結合する前述の多数の医薬品を同定する工程; ここで、該医薬品が、細胞内受容体へのセマホリンの結合に関連した疾患の 診断又は治療に有用であるような方法。 18.遺伝子座に関連した神経疾患の疾病素質について患者を診断する方法であっ て、下記の工程を含む方法: 患者から体細胞を採取する工程; 該体細胞からゲノムDNAを単離する工程; 該ゲノムDNAを、請求の範囲第12項記載のペプチドをコードしているDNA配列 を含むプローブと、該プローブが相同DNAとハイブリッド形成するような条件下 で接触する工程; 前記プローブとハイブリッド形成している該ゲノムDNAの領域を同定する工 程; ここで、該領域の配列の有無が、神経疾患の疾病素質と関連している方法。 19.神経損傷又は疾患、もしくは病的ウイルス感染症を有する患者の治療法であ って、下記の工程を含む方法: 請求の範囲第12項記載のペプチド及び医薬として許容できる担体を含有する 医薬組成物を、治療に有効な量、患者に投与する工程; ここで、前記ペプチドが、該患者において、神経細胞の成長円錐機能又はウ イルス病原性を変更する方法。 20.セマホリン受容体のアミノ酸配列と実質的に類似のアミノ酸配列を含み、か つセマホリン受容体との結合特異性を有する、単離されたポリペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/121,713 US5639856A (en) | 1993-09-13 | 1993-09-13 | Semaphorin gene family |
US08/121,713 | 1993-09-13 | ||
PCT/US1994/010151 WO1995007706A1 (en) | 1993-09-13 | 1994-09-13 | The semaphorin gene family |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09505725A true JPH09505725A (ja) | 1997-06-10 |
JP3544378B2 JP3544378B2 (ja) | 2004-07-21 |
Family
ID=22398364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50926195A Expired - Fee Related JP3544378B2 (ja) | 1993-09-13 | 1994-09-13 | セマホリン遺伝子群 |
Country Status (11)
Country | Link |
---|---|
US (8) | US5639856A (ja) |
EP (1) | EP0721342B1 (ja) |
JP (1) | JP3544378B2 (ja) |
AT (1) | ATE214286T1 (ja) |
AU (1) | AU683494B2 (ja) |
CA (1) | CA2171638C (ja) |
DE (1) | DE69430130T2 (ja) |
DK (1) | DK0721342T3 (ja) |
ES (1) | ES2173922T3 (ja) |
PT (1) | PT721342E (ja) |
WO (1) | WO1995007706A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506994A (ja) * | 2015-02-23 | 2018-03-15 | シーガル セラピューティクス エスアーエス | 非天然セマフォリン3およびそれらの医学的使用 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5639856A (en) * | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5654173A (en) * | 1996-08-23 | 1997-08-05 | Genetics Institute, Inc. | Secreted proteins and polynucleotides encoding them |
US6576441B1 (en) | 1995-12-06 | 2003-06-10 | Sumitomo Pharmaceuticals Company, Limited | Semaphorin Z and gene encoding the same |
DE69738302T2 (de) * | 1996-09-11 | 2008-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Neues semaphorin-gen: semaphorin y |
CA2266325C (en) * | 1996-09-24 | 2012-07-17 | Lxr Biotechnology, Inc. | A family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
US20070299005A1 (en) * | 1996-09-24 | 2007-12-27 | Tanox, Inc. | Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof |
WO1998015628A1 (fr) * | 1996-10-09 | 1998-04-16 | Sumitomo Pharmaceuticals Company, Limited | Nouveau gene de semaphorine: la semaphorine w |
JP4011629B2 (ja) * | 1996-11-15 | 2007-11-21 | 大日本住友製薬株式会社 | 新規セマフォリン遺伝子(i) |
EP0892047A3 (de) * | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US6428965B1 (en) | 1997-07-17 | 2002-08-06 | The Johns Hopkins University | Screening assays for the interaction of semaphorins and neuropilins |
US20030032103A1 (en) * | 1997-09-18 | 2003-02-13 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
US7214497B2 (en) | 1997-10-28 | 2007-05-08 | Immunex Corporation | Viral encoded semaphorin protein receptor DNA and polypeptides |
US6130068A (en) * | 1998-10-26 | 2000-10-10 | Immunex Corporation | Viral encoded semaphorin protein receptor DNA and polypeptides |
US6562949B1 (en) | 1997-10-28 | 2003-05-13 | Immunex Corporation | Antibodies to viral encoded semaphorin protein receptor polypeptides |
CA2307014A1 (en) * | 1997-10-28 | 1999-05-06 | Immunex Corporation | Viral encoded semaphorin protein receptor dna and polypeptides |
US6635421B1 (en) * | 1997-12-09 | 2003-10-21 | Children's Medical Center Corporation | Neuropilins and use thereof in methods for diagnosis and prognosis of cancer |
KR20010033385A (ko) | 1997-12-22 | 2001-04-25 | 오노 야꾸힝 고교 가부시키가이샤 | 펩티드, 사람 펩시노겐 ⅱ 또는 사람 펩신 ⅱ의 측정 방법및 측정용 키트 |
JPH11187882A (ja) * | 1997-12-26 | 1999-07-13 | Ono Pharmaceut Co Ltd | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするcDNA、そのcDNAからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物 |
EP0933425A1 (en) * | 1998-01-30 | 1999-08-04 | Smithkline Beecham Plc | Semaphorin family polypeptides and polynucleotides |
WO1999038885A2 (en) * | 1998-01-30 | 1999-08-05 | Smithkline Beecham Plc | Sbsemvl polypeptides, being members of the semaphorin protein family, and polynucleotides encoding the same |
US7339033B2 (en) * | 1998-06-26 | 2008-03-04 | Genentech, Inc. | Pro1481 |
EP1135488A1 (en) * | 1998-11-26 | 2001-09-26 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Human semaphorin 6a-1 (sema6a-1), a gene involved in neuronal development and regeneration mechanisms during apoptosis, and its use as a potential drug target |
AU770157B2 (en) * | 1999-09-08 | 2004-02-12 | Immunex Corporation | Use of semaphorin for modulation of cellular efflux |
US6750054B2 (en) | 2000-05-18 | 2004-06-15 | Lexicon Genetics Incorporated | Human semaphorin homologs and polynucleotides encoding the same |
US20080213878A1 (en) * | 1999-10-19 | 2008-09-04 | Gregory Donoho | Novel human membrane proteins and polynucleotides encoding the same |
WO2001032707A1 (en) * | 1999-11-02 | 2001-05-10 | Zymogenetics, Inc. | Human semaphorin |
AU4303101A (en) * | 1999-11-08 | 2001-06-04 | General Hospital Corporation, The | Novel semaphorin domains |
EP1268538A2 (en) * | 2000-03-20 | 2003-01-02 | Lexicon Genetics Incorporated | Human secreted proteins and polynucleotides encoding the same |
WO2001090179A2 (en) * | 2000-05-23 | 2001-11-29 | Lexicon Genetics Incorporated | Novel human thrombospondin-like proteins and polynucleotides encoding the same |
WO2002009756A1 (fr) * | 2000-07-28 | 2002-02-07 | Sumitomo Pharmaceuticals Company, Limited | Promoteurs de la regeneration des nerfs contenant un inhibiteur de semaphorine en tant qu'ingredient actif |
CA2493718A1 (en) * | 2001-07-20 | 2003-01-30 | Paul F. Good | Methods for diagnosing and treating alzheimer's disease and parkinson's disease |
EP1429801A1 (en) * | 2001-09-26 | 2004-06-23 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Neuropilin as a novel therapeutic target for modulation of immune reponses |
US7781413B2 (en) * | 2001-10-31 | 2010-08-24 | Board Of Regents, The University Of Texas System | SEMA3B inhibits tumor growth and induces apoptosis in cancer cells |
WO2003066821A2 (en) * | 2002-02-04 | 2003-08-14 | The Johns Hopkins University | Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
FR2876913A1 (fr) * | 2004-10-22 | 2006-04-28 | Centre Nat Rech Scient | Modulation de la transmission synaptique par les semaphorines et ses applications |
US7919594B2 (en) | 2007-02-14 | 2011-04-05 | Vaccinex, Inc. | Human anti-CD100 antibodies |
KR20170080705A (ko) | 2009-05-08 | 2017-07-10 | 백시넥스 인코포레이티드 | 항-cd100 항체 및 이의 사용 방법 |
KR101999872B1 (ko) | 2011-10-11 | 2019-07-12 | 백시넥스 인코포레이티드 | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
WO2014189303A1 (ko) * | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
WO2014209802A1 (en) | 2013-06-25 | 2014-12-31 | Vaccinex, Inc. | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2148587C1 (ru) * | 1991-06-24 | 2000-05-10 | Чирон Корпорейшн | Полипептид и способ его получения, реагент для иммуноанализа, способ определения присутствия антител и способ индукции иммунного ответа |
US5639856A (en) * | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5416197A (en) * | 1993-10-15 | 1995-05-16 | Trustees Of The University Of Pennsylvania | Antibodies which bind human collapsin |
US5807806A (en) * | 1997-06-12 | 1998-09-15 | Nippon Soda Co., Ltd. | Benzoylpyrazole derivatives having specific substituents and herbicide |
-
1993
- 1993-09-13 US US08/121,713 patent/US5639856A/en not_active Expired - Lifetime
-
1994
- 1994-09-13 JP JP50926195A patent/JP3544378B2/ja not_active Expired - Fee Related
- 1994-09-13 CA CA002171638A patent/CA2171638C/en not_active Expired - Fee Related
- 1994-09-13 DE DE69430130T patent/DE69430130T2/de not_active Expired - Lifetime
- 1994-09-13 AT AT94928057T patent/ATE214286T1/de active
- 1994-09-13 AU AU77240/94A patent/AU683494B2/en not_active Ceased
- 1994-09-13 WO PCT/US1994/010151 patent/WO1995007706A1/en active IP Right Grant
- 1994-09-13 ES ES94928057T patent/ES2173922T3/es not_active Expired - Lifetime
- 1994-09-13 EP EP94928057A patent/EP0721342B1/en not_active Expired - Lifetime
- 1994-09-13 PT PT94928057T patent/PT721342E/pt unknown
- 1994-09-13 DK DK94928057T patent/DK0721342T3/da active
-
1997
- 1997-04-08 US US08/835,268 patent/US5807826A/en not_active Expired - Lifetime
- 1997-04-08 US US08/833,391 patent/US6013781A/en not_active Expired - Fee Related
-
1998
- 1998-04-15 US US09/060,610 patent/US6344544B1/en not_active Expired - Fee Related
- 1998-04-15 US US09/060,692 patent/US5935865A/en not_active Expired - Lifetime
-
2002
- 2002-02-04 US US10/067,632 patent/US7153936B2/en not_active Expired - Fee Related
-
2006
- 2006-10-12 US US11/580,373 patent/US20070033669A1/en not_active Abandoned
-
2007
- 2007-06-14 US US11/763,394 patent/US20080312158A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018506994A (ja) * | 2015-02-23 | 2018-03-15 | シーガル セラピューティクス エスアーエス | 非天然セマフォリン3およびそれらの医学的使用 |
Also Published As
Publication number | Publication date |
---|---|
PT721342E (pt) | 2002-09-30 |
AU7724094A (en) | 1995-04-03 |
US7153936B2 (en) | 2006-12-26 |
US5807826A (en) | 1998-09-15 |
US20030166849A1 (en) | 2003-09-04 |
CA2171638A1 (en) | 1995-03-23 |
AU683494B2 (en) | 1997-11-13 |
ATE214286T1 (de) | 2002-03-15 |
JP3544378B2 (ja) | 2004-07-21 |
US20080312158A1 (en) | 2008-12-18 |
EP0721342B1 (en) | 2002-03-13 |
EP0721342A1 (en) | 1996-07-17 |
DE69430130D1 (de) | 2002-04-18 |
US5935865A (en) | 1999-08-10 |
US5639856A (en) | 1997-06-17 |
DE69430130T2 (de) | 2002-08-22 |
US6344544B1 (en) | 2002-02-05 |
DK0721342T3 (da) | 2002-07-15 |
US6013781A (en) | 2000-01-11 |
US20070033669A1 (en) | 2007-02-08 |
CA2171638C (en) | 2001-05-29 |
WO1995007706A1 (en) | 1995-03-23 |
ES2173922T3 (es) | 2002-11-01 |
EP0721342A4 (en) | 1998-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09505725A (ja) | セマホリン遺伝子群 | |
US8680239B2 (en) | Use of RGM and its modulators | |
JP4604228B2 (ja) | Notchタンパク質およびDeltaタンパク質中の結合ドメイン | |
JP3560344B2 (ja) | プロトカドヘリンタンパク質およびその使用 | |
US7781188B1 (en) | Nucleotide and protein sequences of Nogo genes and methods based thereon | |
JPH08502170A (ja) | ノッチタンパク質および核酸に基づいた治療および診断方法ならびに組成物 | |
US20110003971A1 (en) | Modulators and modulation of the interaction between rgm and neogenin | |
US20110137013A1 (en) | Novel collagen-like protein clac, precursor thereof and genes encoding the same | |
JPH06211898A (ja) | 神経α−カテニン | |
MXPA06014402A (es) | Peptido de enlace a heparina. | |
US20100196351A1 (en) | Secreted pate-like proteins | |
JP2003169683A (ja) | 新規脱共役蛋白質mt0029 | |
JP2003325185A (ja) | Itimモチーフを持つ新規な免疫機能抑制分子 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040323 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040402 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090416 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100416 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110416 Year of fee payment: 7 |
|
LAPS | Cancellation because of no payment of annual fees |